This article is a continuation of the previous article that discussed the first day of the 17th Annual Pharmaceutical and Medical Device Compliance Congress. This article covers the highlights from Day 2 of the conference.
As always, the Pharmaceutical and Medical Device Compliance Congress (“PCC”) fully delivered on its promise of two days packed with networking, educational opportunities, and discussion topics highly relevant to the concerns of life science compliance professionals and the emerging issues that require new attention.
The second day featured both plenary sessions as well as many mini-summits. Therefore, this article will briefly cover what we see as the particularly relevant sessions including:
1. Behind the Bribe: Multiple Real-World Perspectives on How Foreign Bribery Occurs, Is Investigated, and Could Be Prevented
2. Truthful and Non-Misleading Communications and Recent First Amendment Cases
3. Leveraging Publicly Available Data: Taking Open Payment Data A Step Further
4. Medical Affairs
5. Recent Developments in Executive Liability Cases: Vascular Solutions, Warner-Chilcott, and Acclarent
Read Full Article in the December 2016 Issue of Life Science Compliance Update